FMR1 and fragile X syndrome: Results will be presented from the initial pilot studies on newborn blood spots of 16,579 infants, focusing on 1st tier newborn screening for fragile X syndrome and confirmatory 2nd tier testing using FMR1 CGG sizing and methylation analyses.